Completed PHASE4 INTERVENTIONAL 1-arm NCT01347996

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia

Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission

Sponsor: Cytovia, Inc.

Conditions Acute Myeloid Leukemia

Interventions histamine dihydrochloride and IL-2

Updated 6 times since 2017 Last updated: Nov 27, 2017 Started: Jul 31, 2009 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Acute Myeloid Leukemia and is currently completed. Cytovia, Inc. leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Dec 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Dec 2017 [monthly]

Completed PHASE4

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cytovia, Inc.
EpiCept Corporation

Data source: Cytovia, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gothenburg, Sweden